| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/16/2004 | EP1235777B1 Vitamin d analogues |
| 06/16/2004 | EP1232176A4 Tumour suppressor factor |
| 06/16/2004 | EP1204417B1 Parenteral cisplatin emulsion |
| 06/16/2004 | EP1194411B1 Benzoylpyridazines |
| 06/16/2004 | EP1152767B1 Method for producing anti-tumor th1 cells |
| 06/16/2004 | EP1071658B1 Btk inhibitors and methods for their identification and use |
| 06/16/2004 | EP1056745B1 6,9-disubstituted 2- trans-(4- aminocyclohexyl) amino]purines |
| 06/16/2004 | EP1030670B1 Use of vitamin d derivatives to enhance efficacy of cytotoxic agents |
| 06/16/2004 | EP0986381B1 Use of diterpenes like hypoestoxides for the manufacture of a medicament for immunosuppression, anticancer and antiviral treatment |
| 06/16/2004 | EP0977725B1 New fatty acid derivatives |
| 06/16/2004 | EP0973730B1 Calcilytic compounds |
| 06/16/2004 | CN1505636A Pharmaceutically active uridine esters |
| 06/16/2004 | CN1505627A Cyclic amp-specific phosphodiesterase inhibitors |
| 06/16/2004 | CN1505618A Dimeric isoflavones |
| 06/16/2004 | CN1505617A Peptides as met-ap2 inhibitors |
| 06/16/2004 | CN1505613A Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-gamma binding agents |
| 06/16/2004 | CN1505603A Substituted benzoic ac id derivatives exhibiting nf-ª—b inhibiting activity |
| 06/16/2004 | CN1505527A Combination therapy using anti-angiogenic agents and tnfa |
| 06/16/2004 | CN1505526A Compositions and methods for wt1 specific immunotherapy |
| 06/16/2004 | CN1505524A Immunopotentiators |
| 06/16/2004 | CN1505521A Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof |
| 06/16/2004 | CN1505511A Use of pyridoindolone derivatives for preparing medicines |
| 06/16/2004 | CN1505510A Medicine combinations using pyridoindolone derivatives and anticancer agent as base |
| 06/16/2004 | CN1504752A Vaughan Tristan J. |
| 06/16/2004 | CN1504749A Experimental investigation of sea pyrimidine inducing tumour cell to blight and die |
| 06/16/2004 | CN1504571A Trichosanthin suicide ENH-TCS, recombination carrier and application thereof |
| 06/16/2004 | CN1504483A NF-ª—B inhibitor, preparing process thereof and application as antineoplastic medicine |
| 06/16/2004 | CN1504481A Apoptosis promoting gene BNIPL, coding albumen and uses thereof |
| 06/16/2004 | CN1504478A Burnet general saponin extract , its preparation method and use |
| 06/16/2004 | CN1504465A Taxotere trihydrate |
| 06/16/2004 | CN1504235A Tie2 receptor-induced gene transfer system for treating target tumor genes |
| 06/16/2004 | CN1504231A Medicine for tumour |
| 06/16/2004 | CN1504218A Medicine composition for tumour and its preparation method |
| 06/16/2004 | CN1504216A Compound formulation of traditional Chinese medicine for assistant treatment of tumour and preparation method thereof |
| 06/16/2004 | CN1504195A Liposome injection liquid of hydrochloric acid daunerubicin and its process |
| 06/16/2004 | CN1504191A Cucurbitacin lipsome preparation method and formulation |
| 06/16/2004 | CN1504189A PDT composition containing benzo porphyrin compound and preparation method |
| 06/16/2004 | CN1153779C Acylated derivative of dioscin and its producing process and use |
| 06/16/2004 | CN1153770C Substitued nitrogen heterocyclic ring as inhibitors of P38 protein kinase |
| 06/16/2004 | CN1153765C 4-aryl-1-phenylalkyl-1,2,3,6-Tetrahydropyridines having neurotrophic and neuroprotective activity |
| 06/16/2004 | CN1153576C Composition and method for treating bladder cancer |
| 06/15/2004 | US6750360 Lipoxin compounds and their use in treating cell proliferative disorders |
| 06/15/2004 | US6750350 Therapy for sexual disorders |
| 06/15/2004 | US6750327 Compositions and method for determining the presence of human PTTG peptide in a sample |
| 06/15/2004 | US6750251 Half-sandwich ruthenium (II) compounds comprising nitrogen containing ligands for treatment of cancer |
| 06/15/2004 | US6750248 Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
| 06/15/2004 | US6750246 C-4 carbonate taxanes |
| 06/15/2004 | US6750245 C7 carbamate substituted taxanes |
| 06/15/2004 | US6750240 Methods of using bis-indolylquinones |
| 06/15/2004 | US6750239 Useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 06/15/2004 | US6750238 Aralkyl ester soft drugs |
| 06/15/2004 | US6750234 Regression of skin tumors, skin homeostases and remodeling, epidermal barrier development, hair growth, and especially wound healing. |
| 06/15/2004 | US6750228 Uncontrolled breakdown of connective tissue by metalloproteases is a feature of many pathological conditions |
| 06/15/2004 | US6750221 Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances |
| 06/15/2004 | US6750217 Anticancer agents; cardiovascular disorders; kinase inhibitor |
| 06/15/2004 | US6750212 Photochemotherapeutic compositions |
| 06/15/2004 | US6750206 Recombinant nucleic acid vector comprising a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface |
| 06/15/2004 | US6750044 For producing pharmaceutically active materials having therapeutic and pharmacologic properties that differ from native vegf protein |
| 06/15/2004 | US6750034 Useful as therapeutic agents for cancer, skin disorders, neuropathic pain, inflammatory, or coagulation diathesis/thrombosis; may also be useful for laundry detergents and skin care products; derived from humans |
| 06/15/2004 | US6749846 Assaying the sensitivity of cells of the ewing's sarcoma to interferon-beta, by cultivation and determining caspase-7 expression of the cells |
| 06/15/2004 | US6749832 Labelled ascorbic acid derivatives |
| 06/15/2004 | US6749587 Modular infusion device and method |
| 06/15/2004 | CA2313302C New metalloprotease inhibitors, the process for preparing them and the pharmaceutical compounds containing them |
| 06/15/2004 | CA2159330C Inhibition of leukocyte adhesion |
| 06/13/2004 | CA2451267A1 Pharmaceutical uses for alpha2delta ligands |
| 06/10/2004 | WO2004049095A2 Betaine and salicylic acid compositions |
| 06/10/2004 | WO2004048574A1 Immunoreceptor proteins |
| 06/10/2004 | WO2004048568A1 UTILIZATION OF mKank GENE IN CANTER THERAPY, CANER DETECTION AND DRUG DISCOVERY |
| 06/10/2004 | WO2004048565A1 Apoptosis-associated protein and use thereof |
| 06/10/2004 | WO2004048512A2 Novel proteins and nucleic acids encoding same |
| 06/10/2004 | WO2004048411A2 Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion |
| 06/10/2004 | WO2004048409A2 Mutants of the tumor necrosis factor alpha with deletion of n-terminal amino acids |
| 06/10/2004 | WO2004048391A1 Silicon compounds to be used as ligands for retinoid receptors |
| 06/10/2004 | WO2004048390A1 Silicon compounds |
| 06/10/2004 | WO2004048386A2 THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS |
| 06/10/2004 | WO2004048382A1 Quinolinyl-pyrrolopyrazoles |
| 06/10/2004 | WO2004048375A1 Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing same |
| 06/10/2004 | WO2004048372A1 Thia-epothilone derivatives for the treatment of cancer |
| 06/10/2004 | WO2004048368A2 Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors |
| 06/10/2004 | WO2004048366A1 2-oxoindoline derivatives |
| 06/10/2004 | WO2004048365A1 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
| 06/10/2004 | WO2004048360A1 Method of synthesizing macrosphelides |
| 06/10/2004 | WO2004048343A1 Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
| 06/10/2004 | WO2004048329A1 Antitumor benzoylsulfonamides |
| 06/10/2004 | WO2004048322A1 Cannabinoid receptor ligands |
| 06/10/2004 | WO2004047925A2 Therapeutic oxidation catalysts |
| 06/10/2004 | WO2004047867A1 Colon cancer metastasis inhibitor |
| 06/10/2004 | WO2004047856A1 Cancer metastasis inhibitor |
| 06/10/2004 | WO2004047832A1 Agent having a destructive effect on malignant tumors and method for the production thereof |
| 06/10/2004 | WO2004047824A1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
| 06/10/2004 | WO2004047818A2 USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS |
| 06/10/2004 | WO2004047811A1 Controlled release formulation of tamsulosin or pharmaceutically acceptable salts thereof for treatment of the signs and symptoms of benign prostatic hyperplasia |
| 06/10/2004 | WO2004047720A2 Methods of inhibiting angiogensis via modification of a lysyl oxidase |
| 06/10/2004 | WO2004030671A3 Use of 4-amino-quinazolines as anti cancer agents |
| 06/10/2004 | WO2004030660A3 Compositions for treatment of prostate and other cancers |
| 06/10/2004 | WO2004030440A3 Synthesis of oligomeric epicatechin and catechin-derived procyanidins |
| 06/10/2004 | WO2004022569A9 Akt inhibitors, pharmaceutical compositions, and uses thereof |
| 06/10/2004 | WO2004020468A3 Interferon beta-like molecules for treatment of cancer |
| 06/10/2004 | WO2004017810A3 Tumor specific oligosaccharide epitopes and use thereof |
| 06/10/2004 | WO2004010957A3 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |